Newsletter | March 10, 2016

03.10.16 -- Obama's Latest Budget: Good News For Biosimilar Makers?

Biosimilar Development
 
Featured Editorial
What Obama's Budget And A Leaked TPP Chapter Mean For Biosimilars
By Anna Rose Welch, Editor, Biosimilar Development   By Anna Rose Welch, Editor, Biosimilar Development
At face value, President Obama's recent budget proposal to lower biologics data exclusivity seems to be good news for biosimilar makers. But recently released information about the controversial TPP negotiations tells another story.
Biopharma Trends That Will Impact The Clinical Space In 2016
By Ed Miseta, Editor, Clinical Leader   By Ed Miseta, Editor, Clinical Leader
One area that is changing quickly, and which promises to impact clinical trials in the coming years, is biopharma. I recently spoke with Jim Esinhart, CEO of Chiltern, about some of these trends, including study protocols, big data, mergers, and new technologies.
Is Pharma Competitiveness Obscuring The Biosimilar Market's Potential?
By Anna Rose Welch, Editor, Biosimilar Development   By Anna Rose Welch, Editor, Biosimilar Development
There is no shortage of research reports in the pharma industry forecasting the potential success or failure of emerging therapeutic markets. However, considering that the industry seems to have erupted into a civil war over whether or not the market will be as successful as predicted, it is difficult to get a sense of where the biosimilar market is actually headed.
Keeping The Patient At The Center Of Drug Delivery Devices
By Bill Welch, CTO, Phillips Medisize   By Bill Welch, CTO, Phillips Medisize
Healthcare is increasingly moving out of the hospital and into the home as self-administration of medications becomes more cost-effective. As the population ages, and people live longer with chronic conditions, the need for safe and effective drug delivery devices will continue to increase.
News Headlines
Biogen And Samsung Bioepis Announce New Data For Three Anti-TNF Biosimilar Development Candidates
Nearly Half Of U.S. Physicians Say They Will Prescribe More Biosimilars, According To New Data From InCrowd
Merck KGaA, Darmstadt, Germany, Initiates Phase 3 Study Of MSB11022, A Proposed Biosimilar Of Adalimumab, In Chronic Plaque Psoriasis
IGBA Calls For Full Transparency And New Timelines For Impact Assessment Of WHO Biological Qualifier Proposal
Biosimilars Blog
 
  Read this week’s blog posts on:
• What Could Happen To Biosimilars Without Pharmacy-Level Substitution?
• Amgen Suit Challenges Sandoz For "Piggybacking" On Enbrel Innovation
• Merck Biosimilar Business Starting Off Small

For these and other headlines, click here.
Connect With Biosimilar Development:
Twitter